Complete Response of Recurrent Squamous Cell Carcinoma of the Lung: Dose the Dose Matter?  by Shin, Sanghoon et al.
mutation in EGFR. Nat Genet 2005;37:
1315–1316.
5. Inukai M, Toyooka S, Ito S, et al. Presence of
epidermal growth factor receptor gene T790M
mutation as a minor clone in non-small cell
lung cancer. Cancer Res 2006;66:7854–7858.
6. Tang X, Shigematsu H, Bekele BN, et al.
EGFR tyrosine kinase domain mutations are
detected in histologically normal respiratory
epithelium in lung cancer patients. Cancer
Res 2005;65:7568–7572.
7. Vikis H, Sato M, James M, et al. EGFR-
T790M is a rare lung cancer susceptibility
allele with enhanced kinase activity. Cancer
Res 2007;67:4665–4670.
Complete Response of
Recurrent Squamous
Cell Carcinoma of the
Lung: Dose the Dose
Matter?
To the Editor:
Bevacizumab is a humanized
monoclonal antibody against vascular
endothelial growth factor and has shown
significant clinical benefit in patients
with various cancers.1 A randomized
phase II study comparing carboplatin
plus paclitaxel with or without bevaci-
zumab in non-small cell lung cancer
patients demonstrated that the addition
of bevacizumab results in an increase in
time to disease progression.2 However,
because of an increased risk of pulmo-
nary hemorrhage with bevacizumab
treatment, a subsequent large phase III
study excluded patients with squamous
cell histology.3 In this report, we present
an elderly patient with recurrent squa-
mous cell carcinoma of the lung who
achieved complete response after treat-
ment with bevacizumab plus carboplatin
and paclitaxel without developing any
hemorrhagic complications.
A 79-year-old man visited our
hospital in July of 2007 with cough and
sputum for a month. The patient under-
went a left upper lobe lobectomy in May
of 2005. Pathology revealed poorly dif-
ferentiated squamous cell carcinoma,
and was staged as T2N1M0. After sur-
gery, four cycles of vinorelbine plus
cisplatin adjuvant chemotherapy were
administered.
Upon admission, his Eastern Co-
operative Oncology Group (ECOG) per-
formance status was 2. Chest computed
tomography (CT) scan revealed recur-
rence of the disease in the left main
bronchus involving the carina, and a
large intraluminal-protruding mass for-
mation with internal necrosis (Figure 1).
Biopsy revealed a squamous cell carci-
noma, pathologically confirming disease
recurrence. Chemotherapy with bevaci-
zumab 7.5 mg/kg combined with carbo-
platin, area under the curve 4, and pacli-
taxel 175 mg/m2 was given once every 3
weeks for 4 cycles. CT scan after the
second cycle showed complete response
(Figure 2) without any evidence of pulmo-
nary hemorrhage. The CT scan after the
fourth cycle showed that complete remis-
sion was maintained. After completing the
regimen, the patient has been receiving
bevacizumab alone for an additional eight
cycles without evidence of recurrence.
The efficacy of bevacizumab in an-
giogenesis inhibition in non-small cell lung
cancer has already been documented,3,4
but comes at a significant price; it is often
associated with adverse side effects, in-
cluding pulmonary hemorrhage, which
may be a life-threatening condition. A
randomized phase II study conducted by
Johnson et al.2 warned of the risk of bleed-
ing in tumors of the squamous cell histol-
ogy, tumors located close to major vessels,
and tumors with necrosis or cativation.
Thus, a phase III trial (ECOG 4599) of
bevacizumab excluded patients with squa-
mous cell histology, brain metastasis, or
anticoagulation medications.3
This is the first case report of an
elderly patient with squamous cell his-
tology who showed complete response
after being treated by bevacizumab
combined with carboplatin and pacli-
taxel. This finding is significant in that
the patient had a higher risk for pulmo-
nary hemorrhage because he was el-
derly, had poor performance status, and
had squamous cell histology, which was
centrally located and showed necrosis.
A recent subset analysis of the ECOG
4599 trial revealed no survival benefits
of bevacizumab plus caboplatin and
paclitaxel for elderly patients (70
years). This finding can be explained by
the higher toxicity when adding bevaci-
zumab to chemotherapy compared with
chemotherapy alone.5
In our case, we used a lower dose
of bevacizumab (7.5 mg/kg), and an
attenuated dose of carboplatin (area un-
der the curve 4) and paclitaxel (175
mg/m2) compared with the ECOG 4599
trial.3 It seems that an attenuated dose of
chemotherapy and a lower dose of bevaci-
zumab can reduce the complications and
the toxicity. Further clinical studies will be
warranted to determine whether bevaci-
zumab is indeed a safe regimen in the
management of squamous cell carcinoma
of the lung and whether an attenuated dose
plays an important role in elderly patients.
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FIGURE 1. Computed tomography
(CT) scan at the time of recurrence. Ne-
crotic mass involved the posterior wall
of the proximal left main bronchus. Bi-
opsy was positive for recurrent squa-
mous cell carcinoma.
FIGURE 2. Computed tomography
(CT) scan after the second cycle of bev-
acizumab, carboplatin, and paclitaxel
chemotherapy. There was complete res-
olution of the necrotic mass involving
the left main stem bronchus.
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Wood-Smoke Exposure
(WSE) as a Predictor of
Response and Survival
in Erlotinib-Treated
Non-small Cell Lung
Cancer (NSCLC)
Patients
To the Editor:
Coal and biomass serves as a major
fuel source for50% of the world’s pop-
ulation.1 In Colombia the prevalence of
wood-smoke exposure (WSE) in areas
having less economic development is
around 24%. The amount of pollution due
to wood-smoke (WS) is elevated; more-
over, it has been calculated that cooking
with wood for 3 h/d, exposes people to
similar amounts of benzo-pyrene as smok-
ing 3 packs of cigarettes/d.1,2 This con-
firms, at least in part, that carcinogens
present in WS are similar to those asso-
ciated with tobacco. There is biologic
plausibility for the association of WSE
and non-small cell lung cancer because
of a similar effect on p53, phospho-p53,
and MDM2 protein expression as occurs
in tobacco smokers.3 Another’s, have
shown an abnormal GSTP-1 genotype,
matrix metalloproteinase expression,
and DNA adduct formation.4
In a previous issue of the JTO,
Arrieta et al.5 described the results of 42
non-small cell lung cancer patients who
were being treated with erlotinib and
had been exposed to WS for approxi-
mately 40 years; 14% of these subgroup
patients had been smokers, overall re-
sponse rate was 34% and clinical benefit
was 67%. Histologic subtype and WSE
were the variables positively influencing
erlotinib response. The study also
showed that the independent factor
which most affected progression-free
survival (PFS) and overall survival was
WSE, and a mean of 17.6 and 19.2
months has being found for each of
these outcomes, respectively. Neverthe-
less, response rate to erlotinib among
smokers was strikingly high (19%), 16%
of the subjects included had stage IIIB
disease and PFS rate for patients with
WSE curiously proved to be greater than
in patients having epidermal growth fac-
tor receptor mutations. Mean follow-up
time was short (4.5 months) and possi-
ble confusion variables (mutational pro-
file, smoking history, comorbidity) were
not suitably debugged.
These findings go against the
scientific aphorisms used for predict-
ing epidermal growth factor receptor-
tyrosine kinase inhibitors response in
patients suffering from lung adenocar-
cinoma, thereby supporting a theory
regarding an alternative route for tu-
mors being produced by WSE. The
main outcomes in a series of 156 pa-
tients suffering from lung adenocarci-
noma treated in Bogota´ (Colombia)
were analyzed in an attempt to ascer-
tain the clinical findings and the bio-
logic hypothesis advanced by Arrieta’s
group. Average age was 64 years, 53%
were female, 39% had never been
smokers, 24% had been considerably
exposed to WS, and 23% of patients
had received erlotinib during some
stage of the disease. Nine of these
subjects had been exposed to WS and
27 had not been. Seven patients having
WSE had been smoking for an average
of 14 years.
Overall response rate to erlotinib
among patients with and without WSE
was 5% and 47% (p  0.0023), re-
spectively. PFS was also significantly
higher among patients who had no
history of WSE and who had received
erlotinib as first-line (p  0.037) and
second-line intervention (p  0.044).
Among patients having WSE history,
overall survival was 6.6 months (5.8 –
7.3) for those treated with erlotinib
and 15.4 months (10.7–20.1) for those
not treated with this compound (p 
0.0022) (Figure 1). Such difference
could be attributed to greater compro-
mise of performance status in the
group with WSE (61% Eastern Coop-
erative Oncology Group 2) due to
the marked deterioration of pulmonary
function.
In line with Arrieta’s proposal, a
multivariate analysis was carried out
for determining the factors influencing
mortality among patients with WSE.
Only performance status (p  0.053)
and gender (p  0.044) were seen to
be significant. Our data did not support
the findings described by Arrieta et al.,
highlighting the need for more consis-
tent studies in this field to be carried
out further.
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